Healio

First-line combination should be ‘new standard’ in advanced lung cancer

Please provide your email address to receive an email when new articles are posted on . Amivantamab-vmjw plus lazertinib significantly improved OS for certain patients with advanced NSCLC compared ...
The American Journal of Managed Care

First-Line Combo Yields Strong Results in Advanced Sarcoma

The phase 1/2 SAINT study is currently investigating intravenous trabectedin plus ipilimumab and nivolumab in the first line for advanced soft tissue sarcoma. The study investigators from City of Hope ...
The American Journal of Managed Care

First-Line Ibrutinib Effective in CLL/SLL With or Without Risk Factors

Ibrutinib shows similar real-world overall survival outcomes for high-risk and non-high-risk CLL/SLL patients, suggesting cytogenetic risk factors do not affect its efficacy. The study utilized a ...
Medscape

First-Line Osimertinib Plus Chemo Extends Survival in NSCLC

The final overall survival (OS) results of the FLAURA2 trial support osimertinib plus chemotherapy as the new first-line standard of care for EGFR-mutated non-small cell lung cancer (NSCLC), according ...
ascopubs.org

Navigating First-Line Treatment Options for Patients With Epidermal Growth Factor Receptor–Positive Non–Small Cell Lung Cancer

Understanding the patterns of acquired resistance to epidermal growth factor receptor (EGFR) TKI treatment has led to more effective combination therapy and continues to drive development of novel ...
Cure Today

First-Line Keytruda Combo Elicits OS Results in Head and Neck Cancers

Keytruda and Efti combination therapy achieved a median overall survival of 17.6 months in head and neck squamous cell carcinoma with PD-L1 CPS less than one. The combination therapy demonstrated a ...